REMARKS

This is in response to the Office Action mailed on June 16, 2004, and the documents cited therewith. Claims 1, 6, 7, 10, 11, 12, 13, 14, and 15 are amended, and claims 2, 3, 4, and 5 are canceled; as a result, claims 1, 6, 7, 8, 9, 10, 11, 12, 13, 14, and 15 are now pending in this application. The amendment to the claims are to clarify the subject matter that applicants' regard as their invention. No new subject matter is added. The Examiner is requested to note that the amendment of claim 1 as presented herein does not surrender any equivalent to which the other substituents may be entitled. Accordingly, Applicant is entitled to a full range of equivalents upon issuance of the instant claims. o new subject matter is added.

Claim Objections

Claim 9 was objected to because the word "prazocin" is misspelled as "prozosin".

Applicants have amended claim 9 to recite the term "prozosin" correctly as -- prazosin --. The correct name for prazosin is found in the Merck Index, Twelfth Edition, at page 1324, entry 7897. A copy of the page from the Merck Index is attached for the Examiner's convenience.

The Examiner stated that claims 4 and 6-13 were objected to as depending from a rejected base claim, but are otherwise in condition for allowance. Applicants have amended claim 1 to include the limitation from claim 4. As all claims now depend directly from allowable claim 1, it is believed that the remaining claims are in condition for allowance. Accordingly, it is respectfully requested that a notice of allowance be issued. i

§103 Rejection of the Claims

Claims 1-3, 5, 14 and 15 were rejected under 35 USC § 103(a) as being unpatentable over Prior et al. (U.S. Patent Application Publication No. 2003/0004143, "Prior '143") in view of Nardella et al. (WO 00/02555, cited by applicants).

Applicants have amended claim 1 to include the subject matter from allowable claim 4. Accordingly, it is believed that this rejection is moot. It is respectfully requested that the rejection under 35 U.S.C. § 103 be withdrawn.

Serial Number: 10/667,208 Filing Date: September 19, 2003

Title: USE OF ETODOLAC TO TREAT HYPERPLASIA

Page 5 Dkt: 103.032US1

Conclusion

Applicant respectfully submits that the claims are in condition for allowance, and notification to that effect is earnestly requested. The Examiner is invited to telephone Applicant's attorney at (612) 373-6968 to facilitate prosecution of this application.

If necessary, please charge any additional fees or credit overpayment to Deposit Account No. 19-0743.

Respectfully submitted,

DENNIS A. CARSON ET AL.

By their Representatives,

SCHWEGMAN, LUNDBERG, WOESSNER & KLUTH, P.A.

P.O. Box 2938

Minneapolis, MN 55402

(612) 373-6968

Date Muller 16, 2004

William F. Prout Reg. No. 33,995

"Express Mail" mailing label number: EV 495 051 045 US

Date of Deposit: November 16, 2004

This paper or fee is being deposited on the date indicated above with the United States Postal Service pursuant to 37 CFR 1.10, and is addressed to The Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.